Pfizer Gets U.S. Order for 10 Million More Covid-19 Pill Courses
2022年1月5日 - 02:29AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. on Tuesday said the U.S. government agreed to buy
another 10 million treatment courses of the company's Paxlovid
Covid-19 pill, bringing the total amount of treatment courses to 20
million.
The New York drugmaker said it expects to deliver about 10
million courses by the end of June, with the remaining 10 million
slated to follow by the end of September.
The U.S. Food and Drug Administration late last month approved
Paxlovid as the first drug that newly infected Covid-19 patients
can take at home to try to ward off serious illness.
The authorization lets doctors prescribe the pill to high-risk
patients age 12 and older early in the course of disease, shortly
after they develop symptoms.
The FDA has also approved the use of a Covid-19 pill from Merck
& Co. and partner Ridgeback Biotherapeutics LP, but the agency
has recommended using the Merck drug only if other authorized drugs
aren't available and medically appropriate, and the drug was less
effective in testing than Pfizer's antiviral pill.
-Jared S. Hopkins contributed to this article
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2022 12:14 ET (17:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 2 2024 まで 3 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2023 まで 3 2024